Novavax | NVAX - Equity Capital And Reserves


Novavax reported $-144.76M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 390.32M 86.99M Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
Geron USD 229.11M 3.24M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
MannKind USD -59.2M 8.17M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026